1. Home
  2. SNSC vs EVAX Comparison

SNSC vs EVAX Comparison

Compare SNSC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SNSC

SunScout Holding Limited Class A Ordinary Shares

HOLD

Current Price

$0.40

Market Cap

26.9M

Sector

N/A

ML Signal

HOLD

Logo Evaxion Biotech

EVAX

Evaxion Biotech

SELL

Current Price

$2.26

Market Cap

25.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SNSC
EVAX
Founded
1998
2008
Country
New Zealand
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.9M
25.5M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
SNSC
EVAX
Price
$0.40
$2.26
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $12.25
AVG Volume (30 Days)
55.7K
★ 75.0K
Earning Date
12-01-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$2.03
52 Week High
$3.15
$6.92

Technical Indicators

Market Signals
Indicator
SNSC
EVAX
Relative Strength Index (RSI) 27.35 36.10
Support Level $0.21 N/A
Resistance Level $1.10 $4.56
Average True Range (ATR) 0.18 0.28
MACD -0.01 -0.07
Stochastic Oscillator 24.62 22.88

Price Performance

Historical Comparison
SNSC
EVAX

About SNSC SunScout Holding Limited Class A Ordinary Shares

SunScout Holding Ltd is a clean-technology company engaged in the design, development, manufacturing, and commercialization of autonomous, solar-powered robotic mowers and related solar energy solutions. Its products are intended as alternatives to petrol-powered and grid-dependent electric lawn mowing equipment. The company's business comprises three lines of products and solutions, which are also its reportable segments: SunScout Products, Solar Power Development Solutions, and Engineering Products and Services. The majority of revenue is derived from the Solar Power Development Solutions segment, which develops and installs solar-energy systems for commercial, industrial, and institutional customers through EPC contracts. Geographically, maximum revenue is derived from New Zealand.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: